{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:28:28Z","timestamp":1793323708292,"version":"4.5.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":384,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Large-scale, real-world data on early initiation of sacubitril\/valsartan in patients newly diagnosed (de novo) with HF with reduced ejection fraction (HFrEF) are limited. We examined the effectiveness of sacubitril\/valsartan versus angiotensin-converting enzyme inhibitor (ACEi)\/angiotensin receptor blocker (ARB) on all-cause and cause-specific hospitalizations among patients with de novo HFrEF from the Optum\u00ae dataset in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included adult patients with de novo HFrEF (diagnosed \u226430 days) with left ventricular ejection fraction (LVEF) \u226440% who were first prescribed with sacubitril\/valsartan or ACEi\/ARB from 1 January 2016 to 31 March 2020. The primary endpoint (all-cause hospitalization) and secondary endpoints were analysed in propensity score-matched cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A cohort of 3290 patients with de novo HFrEF who were prescribed with sacubitril\/valsartan and a propensity-matched cohort of 6580 patients who were prescribed with ACEi\/ARB were analysed. Overall, the mean (SD) age of patients was 63 (14) years, 34% were women, and baseline characteristics were balanced across treatment groups. Hypertension (67%), diabetes (33%) and chronic kidney disease (28%) were highly prevalent comorbidities. Patients in the sacubitril\/valsartan cohort when compared with the ACEi\/ARB cohort had lower annual rates of all-cause hospitalizations [incidence rate ratio (IRR): 0.81, 95% confidence interval (CI): 0.75\u20130.89, P &amp;lt; 0.001], cardiovascular (CV) hospitalizations (IRR: 0.80, 95% CI: 0.73\u20130.87, P &amp;lt; 0.001) and HF hospitalizations (IRR: 0.86, 95% CI: 0.78\u20130.95, P = 0.002).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among patients with de novo HFrEF, sacubitril\/valsartan (compared with that of ACEi\/ARB) was associated with fewer all-cause, CV and HF hospitalizations. These findings are consistent with clinical trial evidence suggesting potential benefits of early initiation of sacubitril\/valsartan in patients with HFrEF, including those soon after diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15183","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T02:22:17Z","timestamp":1738290137000},"page":"1682-1692","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-World Comparative Effectiveness of Sacubitril\/Valsartan Versus RAS Inhibition Alone in Patients with De Novo Heart Failure"],"prefix":"10.1093","volume":"12","author":[{"given":"Ankeet S.","family":"Bhatt","sequence":"first","affiliation":[{"name":"Kaiser Permanente San Francisco Medical Center and Division of Research , San Francisco, California ,","place":["USA"]},{"name":"Division of Cardiovascular Medicine, Stanford University School of Medicine , Palo Alto, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barada P.","family":"Jena","sequence":"additional","affiliation":[{"name":"Novartis Global Service Center , Hyderabad ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylwia","family":"Suminska","sequence":"additional","affiliation":[{"name":"Novartis Global Service Center , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Eid","sequence":"additional","affiliation":[{"name":"Novartis Pharma Services AG, Representative Office for the Middle East and North Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Schwende","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"University of Milano\u2014Bicocca , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"2026021804272458600_ehf215183-bib-0001","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1161\/CIR.0000000000001062","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026021804272458600_ehf215183-bib-0002","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021804272458600_ehf215183-bib-0003","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026021804272458600_ehf215183-bib-0004","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.jacc.2020.06.073","article-title":"Angiotensin receptor-neprilysin inhibition based on history of heart failure and use of renin-angiotensin system antagonists","volume":"76","author":"Ambrosy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026021804272458600_ehf215183-bib-0005","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/ejhf.1670","article-title":"Initiation of sacubitril\/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study","volume":"22","author":"Senni","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026021804272458600_ehf215183-bib-0006","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment\u2014inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026021804272458600_ehf215183-bib-0007","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1002\/ejhf.1830","article-title":"Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient-level database analysis","volume":"22","author":"Messika-Zeitoun","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026021804272458600_ehf215183-bib-0008","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/jce.15784","article-title":"Novel methodology for the evaluation of symptoms reported by patients with newly diagnosed atrial fibrillation: application of natural language processing to electronic medical records data","volume":"34","author":"Reynolds","year":"2023","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026021804272458600_ehf215183-bib-0009","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jacc.2020.12.026","article-title":"Patients hospitalized for de novo versus worsening chronic heart failure in the United States","volume":"77","author":"Greene","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026021804272458600_ehf215183-bib-0010","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40119-021-00252-4","article-title":"Hospitalization rates in patients with heart failure and reduced ejection fraction initiating sacubitril\/valsartan or angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers: a retrospective cohort study","volume":"11","author":"Houchen","year":"2022","journal-title":"Cardiol Ther"},{"key":"2026021804272458600_ehf215183-bib-0011","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/01.mlr.0000118861.56848.ee","article-title":"Comparison of the Elixhauser and Charlson\/Deyo methods of comorbidity measurement in administrative data","volume":"42","author":"Southern","year":"2004","journal-title":"Med Care"},{"key":"2026021804272458600_ehf215183-bib-0012","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"83","author":"Maddox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026021804272458600_ehf215183-bib-0013","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jchf.2021.06.011","article-title":"Drug layering in heart failure: phenotype-guided initiation","volume":"9","author":"Rosano","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026021804272458600_ehf215183-bib-0014","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1016\/j.jacc.2017.04.043","article-title":"Hospitalization for recently diagnosed versus worsening chronic heart failure: from the ASCEND-HF trial","volume":"69","author":"Greene","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026021804272458600_ehf215183-bib-0015","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.jacc.2018.11.049","article-title":"Clinical course of patients with worsening heart failure with reduced ejection fraction","volume":"73","author":"Butler","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026021804272458600_ehf215183-bib-0016","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007034","article-title":"Efficacy and safety of sacubitril\/valsartan in high-risk patients in the PIONEER-HF trial","volume":"14","author":"Berg","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026021804272458600_ehf215183-bib-0017","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1002\/ejhf.1832","article-title":"The prevalence and importance of frailty in heart failure with reduced ejection fraction\u2014an analysis of PARADIGM-HF and ATMOSPHERE","volume":"22","author":"Dewan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026021804272458600_ehf215183-bib-0018","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","article-title":"Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF","volume":"36","author":"Jhund","year":"2015","journal-title":"Eur Heart J"},{"key":"2026021804272458600_ehf215183-bib-0019","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.amjcard.2019.05.031","article-title":"Differences in mortality of new-onset (de-novo) acute heart failure versus acute decompensated chronic heart failure","volume":"124","author":"Younis","year":"2019","journal-title":"Am J Cardiol"},{"key":"2026021804272458600_ehf215183-bib-0020","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006946","article-title":"Reverse cardiac remodeling and outcome after initiation of sacubitril\/valsartan","volume":"13","author":"Januzzi","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2026021804272458600_ehf215183-bib-0021","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1002\/ehf2.13940","article-title":"The benefits of the earlier use of sacubitril\/valsartan in de novo heart failure with reduced ejection fraction patients","volume":"9","author":"Oh","year":"2022","journal-title":"ESC Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/3\/1682\/66956276\/eschf_12_3_1682.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/3\/1682\/66956276\/eschf_12_3_1682.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:27:27Z","timestamp":1771406847000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/3\/1682\/8488362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,1,30]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15183","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,1,30]]},"assertion":[{"value":"2024-06-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}